Other researchers found that Vitamin K and sorafenib treatment in hepatocellular carcinoma promotes inhibitory MET Y1349 phosphorylation, leading to increased PI3K/AKT signaling and inhibition of RAF (Figure 2) [90]. This evidence concerns the gene MET and hepatocellular carcinoma.